# CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients

> **NCT02575261** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Fuda Cancer Hospital, Guangzhou**

## Conditions studied

- EphA2 Positive Malignant Glioma
- CAR-T Cell Immunotherapy

## Interventions

- **BIOLOGICAL:** CAR-T cell immunotherapy

## Key facts

- **NCT ID:** NCT02575261
- **Lead sponsor:** Fuda Cancer Hospital, Guangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-09
- **Primary completion:** 2016-08-15
- **Final completion:** 2016-08-15
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2020-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02575261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02575261, "CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02575261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*